Compare Stocks: OGN, NBIX, JAZZ, and CORT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CORT Corcept Therapeutics	$117.80 -2.8%	$115.29	$28.66 ▼ $126.38	$12.73B	0.4	1.50 million shs	556,021 shs
JAZZ Jazz Pharmaceuticals	$210.39 -2.9%	$243.58	$128.80 ▼ $266.38	$13.66B	0.37	940,398 shs	812,595 shs
NBIX Neurocrine Biosciences	$135.13 -4.4%	$151.25	$122.14 ▼ $186.12	$13.74B	0.4	1.22 million shs	1.57 million shs
OGN Organon & Co.	$13.78 +0.0%	$13.71	$5.69 ▼ $13.83	$3.62B	1.55	5.21 million shs	2.89 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CORT Corcept Therapeutics	0.00%	-0.69%	+7.45%	+33.96%	+63.86%
JAZZ Jazz Pharmaceuticals	-0.76%	-8.17%	-11.82%	-8.95%	+60.05%
NBIX Neurocrine Biosciences	-0.75%	-1.97%	-9.51%	-17.83%	+3.47%
OGN Organon & Co.	-0.22%	+0.44%	+0.95%	+2.03%	+43.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CORT Corcept Therapeutics	$117.80 -2.8%	$115.29	$28.66 ▼ $126.38	$12.73B	0.4	1.50 million shs	556,021 shs
JAZZ Jazz Pharmaceuticals	$210.39 -2.9%	$243.58	$128.80 ▼ $266.38	$13.66B	0.37	940,398 shs	812,595 shs
NBIX Neurocrine Biosciences	$135.13 -4.4%	$151.25	$122.14 ▼ $186.12	$13.74B	0.4	1.22 million shs	1.57 million shs
OGN Organon & Co.	$13.78 +0.0%	$13.71	$5.69 ▼ $13.83	$3.62B	1.55	5.21 million shs	2.89 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CORT Corcept Therapeutics	0.00%	-0.69%	+7.45%	+33.96%	+63.86%
JAZZ Jazz Pharmaceuticals	-0.76%	-8.17%	-11.82%	-8.95%	+60.05%
NBIX Neurocrine Biosciences	-0.75%	-1.97%	-9.51%	-17.83%	+3.47%
OGN Organon & Co.	-0.22%	+0.44%	+0.95%	+2.03%	+43.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CORT Corcept Therapeutics	2.75	Moderate Buy	$138.17	17.29% Upside
JAZZ Jazz Pharmaceuticals	3.00	Buy	$291.25	38.43% Upside
NBIX Neurocrine Biosciences	2.83	Moderate Buy	$201.14	48.85% Upside
OGN Organon & Co.	1.71	Reduce	$11.40	-17.24% Downside

Current Analyst Ratings Breakdown

Latest OGN, NBIX, JAZZ, and CORT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	NBIX Neurocrine Biosciences	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Market Perform	$164.00 ➝ $150.00
10/8/2026	OGN Organon & Co.	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
10/8/2026	JAZZ Jazz Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$299.00 ➝ $296.00
10/7/2026	JAZZ Jazz Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$281.00 ➝ $286.00
10/6/2026	NBIX Neurocrine Biosciences	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$207.00
9/30/2026	JAZZ Jazz Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$325.00
9/29/2026	NBIX Neurocrine Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy (B-) ➝ Hold (C+)
9/29/2026	NBIX Neurocrine Biosciences	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$231.00 ➝ $214.00
9/28/2026	CORT Corcept Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
9/24/2026	CORT Corcept Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
9/24/2026	JAZZ Jazz Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$337.00

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CORT Corcept Therapeutics	$830.81M	15.33	$0.88 per share	134.25	$6.16 per share	19.12
JAZZ Jazz Pharmaceuticals	$4.60B	2.97	$15.67 per share	13.43	$71.07 per share	2.96
NBIX Neurocrine Biosciences	$3.37B	4.07	$4.75 per share	28.42	$32.63 per share	4.14
OGN Organon & Co.	$6.22B	0.58	$5.76 per share	2.39	$2.89 per share	4.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CORT Corcept Therapeutics	$99.65M	$0.42	280.48	33.85	N/A	6.52%	8.26%	6.45%	11/4/2026 (Estimated)
JAZZ Jazz Pharmaceuticals	-$356.15M	$14.50	14.51	9.49	0.20	20.45%	33.97%	13.02%	11/4/2026 (Estimated)
NBIX Neurocrine Biosciences	$478.60M	$6.82	19.81	14.28	0.66	20.91%	22.43%	15.64%	11/2/2026 (Estimated)
OGN Organon & Co.	$187M	$0.77	17.89	4.00	1.28	3.41%	88.97%	6.03%	11/9/2026 (Estimated)

Latest OGN, NBIX, JAZZ, and CORT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	OGN Organon & Co.	$0.88	N/A	N/A	N/A	$1.58 billion	N/A
11/4/2026	Q3 2026	CORT Corcept Therapeutics	$0.8130	N/A	N/A	N/A	$323.90 million	N/A
11/4/2026	Q3 2026	JAZZ Jazz Pharmaceuticals	$6.39	N/A	N/A	N/A	$1.20 billion	N/A
11/2/2026	Q3 2026	NBIX Neurocrine Biosciences	$1.91	N/A	N/A	N/A	$1.04 billion	N/A
8/3/2026	Q2 2026	JAZZ Jazz Pharmaceuticals	$6.18	$5.71	-$0.47	$2.78	$1.11 billion	$1.21 billion
7/31/2026	Q2 2026	NBIX Neurocrine Biosciences	$1.65	$2.85	+$1.20	$1.39	$891.16 million	$959.00 million
7/29/2026	Q2 2026	CORT Corcept Therapeutics	$0.0243	$0.36	+$0.3357	$0.36	$221.15 million	$256.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.58%	N/A	10.39%	N/A

Latest OGN, NBIX, JAZZ, and CORT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/31/2026	OGN Organon & Co.	quarterly	$0.02	0.58%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CORT Corcept Therapeutics	N/A	2.86	2.77
JAZZ Jazz Pharmaceuticals	0.69	1.78	1.58
NBIX Neurocrine Biosciences	N/A	1.87	1.75
OGN Organon & Co.	8.43	1.95	1.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CORT Corcept Therapeutics	93.61%
JAZZ Jazz Pharmaceuticals	89.14%
NBIX Neurocrine Biosciences	92.59%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
CORT Corcept Therapeutics	20.70%
JAZZ Jazz Pharmaceuticals	4.10%
NBIX Neurocrine Biosciences	4.60%
OGN Organon & Co.	1.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CORT Corcept Therapeutics	730	108.10 million	85.72 million	Optionable
JAZZ Jazz Pharmaceuticals	2,890	64.92 million	62.25 million	Optionable
NBIX Neurocrine Biosciences	2,000	101.65 million	96.97 million	Optionable
OGN Organon & Co.	10,000	262.61 million	258.36 million	Not Optionable

OGN, NBIX, JAZZ, and CORT Headlines

Recent News About These Companies

Organon & Co. (NYSE:OGN) Stock Now Rated "Reduce" by Wall Street Brokerages

October 13 at 10:28 AM | marketbeat.com

Organon & Co. $OGN Stock: Douglas Lane & Associates LLC Trims Position

October 10 at 4:04 AM | marketbeat.com

Organon & Co stock hits 52-week high at 13.79 USD

October 7, 2026 | investing.com

Organon & Co. (NYSE:OGN) Hits New 12-Month High - Still a Buy?

October 7, 2026 | marketbeat.com

Organon stock presents new VTAMA analysis ahead of November results

October 4, 2026 | ad-hoc-news.deA

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

October 2, 2026 | zacks.com

Organon Canada Announces Approval And Availability Of NDUVRA® (Tapinarof Cream), 1%, For Moderate To Severe Atopic Dermatitis In Adult and Pediatric Patients 2 Years Of Age ...

September 28, 2026 | marketscreener.comM

Organon Says Nduvra Cream Gets Canada Approval for Atopic Dermatitis

September 28, 2026 | marketscreener.comM

Organon Canada Gets Approval For NDUVRA 1% Non-Steroid Cream For Atopic Dermatitis

September 28, 2026 | rttnews.com

Organon Canada announces the Approval and Availability of NDUVRA® (tapinarof cream), 1%, a New Steroid-Free Topical Treatment for Moderate to Severe Atopic Dermatitis in Adult ...

September 28, 2026 | marketscreener.comM

September 21, 2026 | zacks.com

Organon & Co. (NYSE:OGN) Given Consensus Recommendation of "Reduce" by Brokerages

September 18, 2026 | marketbeat.com

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

September 14, 2026 | businesswire.com

Organon: A Merger-Arbitrage Hold With Limited Upside

September 12, 2026 | seekingalpha.com

Orogen Royalties Acquires the Serpent Gold Project in Nevada

September 10, 2026 | accessnewswire.comA

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

September 8, 2026 | zacks.com

Organon & Co. (OGN) Stock Price, News, Quote & History - Yahoo Finance

September 4, 2026 | finance.yahoo.com

Organon & Co. (OGN) Stock Earnings Call Transcripts - Yahoo Finance

September 1, 2026 | finance.yahoo.com

National Can-RISE Study to Help Close Critical Gaps in Menopause Research

August 27, 2026 | globenewswire.com

Organon & Co. (OGN)

August 13, 2026 | sg.finance.yahoo.com

Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability

August 11, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN, NBIX, JAZZ, and CORT Company Descriptions

Corcept Therapeutics NASDAQ:CORT

$117.80 -3.39 (-2.80%)

Closing price 04:00 PM Eastern

Extended Trading

$117.20 -0.59 (-0.51%)

As of 05:49 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Jazz Pharmaceuticals NASDAQ:JAZZ

$210.39 -6.36 (-2.93%)

Closing price 04:00 PM Eastern

Extended Trading

$211.48 +1.09 (+0.52%)

As of 05:33 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Neurocrine Biosciences NASDAQ:NBIX

$135.13 -6.24 (-4.41%)

Closing price 04:00 PM Eastern

Extended Trading

$135.32 +0.19 (+0.14%)

As of 05:37 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Organon & Co. NYSE:OGN

$13.78 +0.01 (+0.04%)

Closing price 03:59 PM Eastern

Extended Trading

$13.78 0.00 (0.00%)

As of 04:15 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OGN, NBIX, JAZZ, and CORT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OGN, NBIX, JAZZ, and CORT Earnings

Compare Dividends

Latest OGN, NBIX, JAZZ, and CORT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OGN, NBIX, JAZZ, and CORT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN, NBIX, JAZZ, and CORT Company Descriptions

Corcept Therapeutics NASDAQ:CORT

Jazz Pharmaceuticals NASDAQ:JAZZ

Neurocrine Biosciences NASDAQ:NBIX

Organon & Co. NYSE:OGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OGN, NBIX, JAZZ, and CORT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OGN, NBIX, JAZZ, and CORT Earnings

Compare Dividends

Latest OGN, NBIX, JAZZ, and CORT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OGN, NBIX, JAZZ, and CORT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN, NBIX, JAZZ, and CORT Company Descriptions

Corcept Therapeutics NASDAQ:CORT

Jazz Pharmaceuticals NASDAQ:JAZZ

Neurocrine Biosciences NASDAQ:NBIX

Organon & Co. NYSE:OGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools